Physician profile
John Robert Silver
NPI 1417925504
$1,295.92
in general payments reported to CMS, 2019-2025
13 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2021: $343 · 2022: $186 · 2023: $59.25 · 2024: $43.77 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $334.69 | 2021-2025 | |
| Optinose US, INC. | $293.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $154.74 | 2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2019 | |
| Aerin Medical INC. | $119.93 | 2019 | |
| Medtronic USA, INC. | $110.00 | 2019 | |
| Intersect Ent, INC. | $39.33 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.77 | 2023 | Dupixent |
| Kaleo, INC. | $24.76 | 2019 | |
| Acclarent, INC | $21.81 | 2021 | |
| Medtronic, INC. | $15.47 | 2025 | Propel |
| Alk-Abello, INC | $15.18 | 2021 | |
| Innocoll Pharmaceuticals Limited | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.